The Filing Desk

Amarin vs Vanda Pharmaceuticals

Amarin AMRN · Vanda Pharmaceuticals VNDA · Pharmaceuticals

Vanda Pharmaceuticals reported revenue of $216 million in fiscal 2025, about the same as Amarin's $214 million in fiscal 2025. Amarin's revenue fell 6.5% in its latest year, and Vanda Pharmaceuticals' grew 8.7%. Amarin had an operating margin of -23.5%, against -70.0% at Vanda Pharmaceuticals.

Side by side

AmarinVanda Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$214M$216M
Revenue growth−6.5%8.7%
Revenue growth a year, last 5 years−19.0%−2.7%
Gross margin56.6%—
Operating margin−23.5%−70.0%
Net margin−18.2%−102.0%
Free cash flow—−$110M
Free cash flow margin—−51.1%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count1.0%1.3%
Last close$11.26$3.67
P/E at the last close——
Insider trades, last 12 months—sold $2.8 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
AmarinVanda Pharmaceuticals
Operating margin
Percent of revenue
AmarinVanda Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AmarinVanda Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Amarin and Vanda Pharmaceuticals pages.